By Stephen Nakrosis
Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.
In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71.
Portage said the data showed both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma.
The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7.
Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 27, 2025 18:02 ET (22:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.